secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001104659-24-054933
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q1 revenue $10.8M (+35% YoY); net loss $22.2M; FY guidance $50-53M
-----------------------------------------------------------------------

- Q1 revenue $10.8M (+35% YoY); US HF revenue $9.7M (+43%); active implanting centers 190 (+56% YoY).
- Net loss $22.2M ($1.04/shr) vs $11.4M ($0.55) prior year; SG&A $28.3M (+84%) from stock-based comp modification for former CEO.
- Full-year 2024 revenue guidance $50-53M; Q2 2024 revenue expected $11.3-12.3M.
- Kevin Hykes appointed CEO Feb 12; BeAT-HF data published in European Journal of Heart Failure.
- Compensation Committee approved $50k bonus to Paul Verrastro for management transition support.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924054933/0001104659-24-054933-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924054933/tm2412998d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-054933

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer